Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Real-World Analysis Reveals Gaps in HRR Testing and PARP Inhibitor Treatment in mCRPC

February 22nd 2025

Most patients with mCRPC included in a real-world study did not undergo HRR testing at the time of diagnosis.

Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC

February 21st 2025

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

67Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PSMA+ mCRPC

February 20th 2025

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

Dr Oh on the Development of Targeted Therapies in Prostate Cancer

February 17th 2025

William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.

Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management

February 17th 2025

Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.

OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer

February 17th 2025

Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.

Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC

February 14th 2025

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

February 14th 2025

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC

February 14th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

Darolutamide Plus ADT Is Efficacious in mHSPC Regardless of Disease Volume

February 13th 2025

The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.

EBRT With or Without STAD Shows Improved 15-Year Survival in Prostate Cancer

February 13th 2025

Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.

Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC

February 13th 2025

A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.

G-CSF Allows for Efficacious Dose of Docetaxel With ARASENS Regimen in mHSPC

February 13th 2025

G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.

Advanced Therapies and Innovative Options for Prostate Cancer Care

February 13th 2025

Multidisciplinary treatment addresses all facets of patient health, resulting in personalized prostate cancer treatment plans that optimize outcomes.

Illuccix PSMA-PET Imaging Agent Receives UK Approval in Prostate Cancer

February 13th 2025

The UK Medicines and Healthcare Products Regulatory Agency has approved the kit for the preparation of gallium-68 gozetotide injection.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12th 2025

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Dr Berchuck on Next Steps for Evaluating a Novel Liquid Biopsy for PSMA in mCRPC

January 23rd 2025

Jacob E. Berchuck, MD, shares next steps in research for a novel epigenomic liquid biopsy test for detecting PSMA in castration-resistant prostate cancer.

Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents

January 22nd 2025

The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.

Rapid, At-Home PSA Screening Test Gains Approval in UAE for Early Detection of Prostate Cancer

January 21st 2025

The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.

Development of LAVA-1207 Discontinues in mCRPC

January 20th 2025

The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.